Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20(10):2698–704.
Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am Fam Physician. 2006;74(4):594–600.
Sinaii N, Cleary SD, Younes N, Ballweg ML, Stratton P. Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience. Fertil Steril. 2007;87(6):1277–86.
Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.
Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril. 2008;89(3):538–45.
Ballard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study--part 1. BJOG. 2008;115(11):1382–91.
Culley L, Law C, Hudson N, Denny E, Mitchell H, Baumgarten M, et al. The social and psychological impact of endometriosis on women's lives: a critical narrative review. Hum Reprod Update. 2013;19(6):625–39.
Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, de Bie B, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.
Fadhlaoui A, de la Jolinière JB, Feki A. Endometriosis and infertility: how and when to treat? Front Surg. 2014;1(24).
Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: National Estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Investig. 2017;82(5):453–61.
Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125(1):55–62.
Zanelotti A, Decherney AH. Surgery and endometriosis. Clin Obstet Gynecol. 2017;60(3):477–84.
Endometriosis: diagnosis and management. National Institute for Health Care and Excellence (NICE). https://www.nice.org.uk/guidance/ng73. Published September 2017. Accessed September 2018.
Leyland N, Casper R, Laberge P, Singh SS, SOGC. Endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32(7 Suppl 2):S1–32.
Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril. 2004;82(4):878–84.
Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–61.
Kondo W, Bourdel N, Tamburro S, Cavoli D, Jardon K, Rabischong B, et al. Complications after surgery for deeply infiltrating pelvic endometriosis. BJOG. 2011;118(3):292–8.
Prentice A, Deary AJ, Bland E. Progestogens and anti-progestogens for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;2:CD002122.
Prentice A, Deary AJ, Goldbeck-Wood S, Farquhar C, Smith SK. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev. 2007;2:CD000346.
Oettel M, Carol W, Elger W. A 19-norprogestin without 17a-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today. 1995;31:517–36.
Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008;73(2):222–31.
Strowitzki T, Faustmann T, Gerlinger C, Schumacher U, Ahlers C, Seitz C. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int J Women's Health. 2015;7:393–401.
Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynaecol Obstet. 2010;108(1):21–5.
Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2010;151(2):193–8.
Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–41.
Petraglia F, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285(1):167–73.
Lang J, Yu Q, Zhang S, et al. Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study. J Women's Health (Larchmt). 2018;27(2):148–55.
Yu Q, Zhang S, Li H, et al. Dienogest for treatment of endometriosis in women: a 28-week, open-label, extension study. J Women's Health (Larchmt). 2019;28(2):170–7.
American Society For Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67(5):817–21.
Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29(5):383–90.
Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis associated pelvic pain measured on a visual analog scale: analysis of two placebo controlled, randomized trials. Health Qual Life Outcomes. 2010;8:138.
Chudnoff SG, Nichols JE Jr, Levie M. Hysteroscopic essure inserts for permanent contraception: extended follow-up results of a phase III multicenter international study. J Minim Invasive Gynecol. 2015;22(6):951–60.
Guy W. ECDEU Assessment Manual for Psychopharmacology (028 clinical global impressions [CGI]). Rockville: National Institutes of Health; 1976. p. 218–22.
Heinemann K, Imthurn B, Marions L, Faustmann T. VIPOS: a large non-interventional study examining the safety of dienogest and other hormonal treatments for endometriosis in real-world clinical practice. Poster presented at: the Society of Endometriosis and Uterine Disorders; 2018; Florence, Italy.
Imthurn B, Marions L, Möhner S, Becker K, Faustmann T, Heinemann K. Baseline patient and disease characteristics of >27,000 women with endometriosis enrolled in the VIPOS study (Abstract). Fertil Steril. 2018;110(4):e392.
Kim BK, Chu MK, Lee TG, Kim JM, Chung CS, Lee KS. Prevalence and impact of migraine and tension-type headache in Korea. J Clin Neurol. 2012;8(3):204–11.
Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193–210.
Allais G, Chiarle G, Sinigaglia S, Benedetto C. Menstrual migraine: a review of current and developing pharmacotherapies for women. Expert Opin Pharmacother. 2018;19(2):123–36.
Pavlović JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87(1):49–56.
Darney PD. The androgenicity of progestins. Am J Med. 1995;98(1A):104S–10S.
Park SY, Kim SH, Chae HD, Kim CH, Kang BM. Efficacy and safety of dienogest in patients with endometriosis: a single-center observational study over 12 months. Clin Exp Reprod Med. 2016;43(4):215–20.
Alomar MJ. Factors affecting the development of adverse drug reactions (review article). Saudi Pharm J. 2014;22(2):83–94.
Untersmayr E, Jensen AN, Walch K. Sex hormone allergy: clinical aspects, causes and therapeutic strategies - update and secondary publication. World Allergy Organ J. 2017;10(1):45.